

10/593808  
IAP9/Rec'd PCT/PTO 20 SEP 2006  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig A. Coburn et al.	
Serial No.:	To Be Assigned	Case No.: 21664YP
US Nat'l Filing Date:	September 20, 2006	
Int'l Appl'n No.	PCT/US2005/010224	
Int'l Filing Date:	March 25, 2005	
For:	2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS	

Mail Stop PCT  
Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT September 20, 2006  
EXPRESS MAIL NO. EL989585570US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,  
Alexandria, Virginia 22313-1450

MAILED BY Christina Cuffe  
DATE 9-20-06

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.


In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference C on the accompanying PTO 1440 form was cited in the International Search Report for this application. A copy of the International Search Report and Written Opinion of the International Searching Authority is enclosed with the Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: September 20, 2006

21664YP

[illegible][illegible]Date  
Considered

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

21664YP

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006